TY - JOUR
T1 - Effect of grape products on blood pressure
T2 - a systematic review and meta-analysis of randomized controlled trials
AU - Asbaghi, Omid
AU - Naeini, Fatemeh
AU - Moodi, Vihan
AU - Najafi, Moein
AU - Shirinbakhshmasoleh, Mina
AU - Rezaei Kelishadi, Mahnaz
AU - Hadi, Amir
AU - Ghaedi, Ehsan
AU - Fadel, Abdulmnannan
N1 - Publisher Copyright:
© 2021, Published with license by Taylor & Francis Group, LLC. © 2021 Omid Asbaghi, Fatemeh Naeini, Vihan Moodi, Moein Najafi, Mina Shirinbakhshmasoleh, Mahnaz Rezaei Kelishadi, Amir Hadi, Ehsan Ghaedi and Abdulmnannan Fadel.
PY - 2021
Y1 - 2021
N2 - Previous studies have suggested that grape and its products may possess blood pressure (BP)-lowering properties. Due to inconsistencies in results, we aimed to systematically examine the effect of grape products on BP by conducting a meta-analysis of randomized controlled trials (RCTs). PubMed, Scopus, Web of Science (ISI), and Cochrane Library databases were comprehensively searched until March 2020. Human clinical trials which reported the effect of grape products supplementation on systolic BP (SBP) and diastolic BP (DBP) were included. Data were pooled using a random-effects model and expressed as a weighted mean difference (WMD) with a 95% confidence interval (CI). Twenty-eight studies comprising a total of 1344 subjects were included in our meta-analysis. The overall outcome of the meta-analysis indicates that grape products consumption can significantly reduce SBP (WMD: −3.40 mmHg, 95% CI: −6.55, −0.24, p = .03, I2 = 93.4%) and DBP (WMD: −1.69 mmHg, 95% CI: −3.12, −0.27, p = .01, I2 = 80.4%). This meta-analysis found a moderate and statistically significant reduction for either SBP or DBP with grape products compared with controls. Additional high-quality studies are needed to further evaluate the causal conclusions.
AB - Previous studies have suggested that grape and its products may possess blood pressure (BP)-lowering properties. Due to inconsistencies in results, we aimed to systematically examine the effect of grape products on BP by conducting a meta-analysis of randomized controlled trials (RCTs). PubMed, Scopus, Web of Science (ISI), and Cochrane Library databases were comprehensively searched until March 2020. Human clinical trials which reported the effect of grape products supplementation on systolic BP (SBP) and diastolic BP (DBP) were included. Data were pooled using a random-effects model and expressed as a weighted mean difference (WMD) with a 95% confidence interval (CI). Twenty-eight studies comprising a total of 1344 subjects were included in our meta-analysis. The overall outcome of the meta-analysis indicates that grape products consumption can significantly reduce SBP (WMD: −3.40 mmHg, 95% CI: −6.55, −0.24, p = .03, I2 = 93.4%) and DBP (WMD: −1.69 mmHg, 95% CI: −3.12, −0.27, p = .01, I2 = 80.4%). This meta-analysis found a moderate and statistically significant reduction for either SBP or DBP with grape products compared with controls. Additional high-quality studies are needed to further evaluate the causal conclusions.
KW - Blood pressure
KW - Grape products
KW - Hypertension
KW - Meta-analysi
KW - Systematic review
UR - http://www.scopus.com/inward/record.url?scp=85104662715&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85104662715&partnerID=8YFLogxK
U2 - 10.1080/10942912.2021.1901731
DO - 10.1080/10942912.2021.1901731
M3 - Review article
AN - SCOPUS:85104662715
SN - 1094-2912
VL - 24
SP - 627
EP - 645
JO - International Journal of Food Properties
JF - International Journal of Food Properties
IS - 1
ER -